BioSpace News Archive

Catalyst Biosciences, Inc. today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a pivotal Phase 3 trial design for Marzeptacog alfa (activated) – MarzAA. The open-label trial will evaluate the effi

Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of their collaboration to explore treatment opportunities of the COVID-19 virus, for the benefit of the most vulnerable cancer patients with cardiovascular issues and/or a weakened immune system.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the fully automated high throughput MosaiQ system in response to the global COVID-19 pandemic.

Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-β antisense drug candidate, announced today that Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500

Data demonstrate turnover is faster than previously described for cccDNA, a necessary component required for the establishment and persistence of HBV infection

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned website, www.aprea.com.

Metropolitan Dermatology, a leading dermatology practice with locations throughout New Jersey and New York, is expanding patient services to include telemedicine as a solution to these trying times.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2019.

Cell Types and MindScope research programs to enter new stages of resource generation and discovery; another neuroscience division to launch in 2022

MBio Diagnostics announced an expanded scope contract with the US Defense Advanced Research Projects Agency, where DARPA will apply additional resources and funds to accelerate progress towards FDA approval for MBio’s LightDeck® platform.